Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 29:3:92.
doi: 10.3389/fonc.2013.00092. eCollection 2013.

Opportunities and challenges for successful use of bevacizumab in pediatrics

Amy Barone  1 , Joshua B Rubin
Affiliations

Opportunities and challenges for successful use of bevacizumab in pediatrics

Amy Barone et al. Front Oncol. .

Abstract

Bevacizumab (Avastin) has rapidly gained status as a broadly active agent for malignancies of several different histologies in adults. This activity has spawned a range of uses in pediatrics for both oncologic and non-oncologic indications. Early analyses indicate that pediatric cancers exhibit a spectrum of responses to bevacizumab that suggest its activity may be more limited than in adult oncology. Most exciting, is that for low-grade tumors that threaten vision and hearing, there is not only evidence for objective tumor response but for recovery of lost function as well. In addition to oncological indications, there is a range of uses for non-oncologic disease for which bevacizumab has clear activity. Finally, a number of mechanisms have been identified as contributing to bevacizumab resistance in cancer. Elucidating these mechanisms will guide the development of future clinical trials of bevacizumab in pediatric oncology.

Keywords: VEGF; anti-angiogenic; bevacizumab; glioblastoma; pediatric.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aguilera D. G., Goldman S., Fangusaro J. (2011). Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatr. Blood Cancer 56, 491–49410.1002/pbc.22868 - DOI - PubMed
    1. Bass M. B., Sherman S. I., Schlumberger M. J., Davis M. T., Kivman L., Khoo H. M., et al. (2010). Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 95, 5018–502710.1210/jc.2010-0947 - DOI - PubMed
    1. Batchelor T. T., Sorensen A. G., di Tomaso E., Zhang W. T., Duda D. G., Cohen K. S., et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–9510.1016/j.ccr.2006.11.021 - DOI - PMC - PubMed
    1. Ben Bashat D., Artzi M., Ben Ami H., Aizenstein O., Blumenthal D. T., Bokstein F., et al. (2012). Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain tumors. PLoS ONE 7:e49416.10.1371/journal.pone.0049416 - DOI - PMC - PubMed
    1. Benesch M., Windelberg M., Sauseng W., Witt V., Fleischhack G., Lackner H., et al. (2008). Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann. Oncol. 19, 807–81310.1093/annonc/mdm510 - DOI - PubMed

LinkOut - more resources